Microbiome Gut-Brain Axis Therapy represents an emerging therapeutic approach that modulates the gut microbiota to treat neurodegenerative diseases. The gut-brain axis is a bidirectional communication network linking the intestinal microbiome with brain function through neural, endocrine, immunological, and metabolic pathways[1]. This therapy encompasses multiple approaches including fecal microbiota transplantation (FMT), probiotics, prebiotics, and postbiotics, each targeting different aspects of the microbiome-gut-brain connection[2].
| Property | Value |
|---|---|
| Category | Emerging Therapy |
| Target | Gut microbiome composition |
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS |
| Key Interventions | FMT, Probiotics, Prebiotics, Postbiotics |
| Mechanism | Bidirectional neural-immune-metabolic signaling |
The vagus nerve serves as the primary parasympathetic connection between the gut and brain, transmitting signals bidirectionally and influencing neuroinflammation, mood, and cognitive function[3]. The enteric nervous system, often called the "second brain," contains approximately 500 million neurons and communicates extensively with the central nervous system[4]. Additionally, gut bacteria directly produce neurotransmitters including 95% of the body's serotonin, gamma-aminobutyric acid (GABA), and dopamine precursors[5].
The hypothalamic-pituitary-adrenal (HPA) axis mediates cortisol-mediated stress responses that can exacerbate neurodegeneration when chronically activated[6]. Short-chain fatty acids (SCFAs)—primarily acetate, propionate, and butyrate—produced by bacterial fermentation of dietary fiber, exert profound effects on brain function including epigenetic regulation, neurogenesis, and microglial maturation[7]. Bile acid signaling through farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) receptors influences neuroinflammation and mitochondrial function[8].
The gut-associated lymphoid tissue (GALT) constitutes the largest immune organ in the body and maintains constant dialogue with the systemic immune system[9]. Dysbiosis-induced increased intestinal permeability ("leaky gut") allows bacterial lipopolysaccharide (LPS) and other pro-inflammatory molecules to enter circulation, promoting systemic inflammation that reaches the brain[10]. Microglial priming by gut-derived inflammatory signals enhances neuroinflammatory responses to protein aggregation in neurodegenerative diseases[11].
Alzheimer's disease (AD) is consistently associated with gut microbiome dysbiosis characterized by reduced microbial diversity and altered composition[12]. Patients with AD show increased pro-inflammatory bacteria (Proteobacteria, Bacteroidetes) and decreased anti-inflammatory commensals (Bifidobacterium, Firmicutes)[13]. Elevated LPS has been detected in AD brain tissue, co-localizing with amyloid-beta plaques, suggesting bacterial endotoxins may contribute to amyloidogenesis[14]. The SCFA balance is disrupted in AD, with reduced butyrate levels correlating with cognitive impairment[15].
Parkinson's disease (PD) frequently presents with gastrointestinal dysfunction years before motor symptoms appear, with constipation being one of the earliest prodromal markers[16]. Alpha-synuclein pathology has been identified in the enteric nervous system of PD patients, suggesting a potential gut origin of the disease process[17]. Studies consistently show reduced Faecalibacterium and increased Escherichia/Shigella in PD patients[18]. Remarkably, truncal vagotomy reduces PD risk by approximately 40%, providing strong evidence for the gut-origin hypothesis[19].
ALS patients exhibit altered microbiome composition with reduced microbial diversity and decreased butyrate-producing bacteria[20]. The SOD1 mouse model of ALS shows improved survival and reduced neuroinflammation when raised in germ-free conditions or treated with antibiotics, supporting a microbiome-neuroinflammation connection[21]. Human studies demonstrate correlations between specific microbial taxa and ALS progression rates[22].
FMT restores healthy microbiome composition by transferring fecal material from healthy donors to patients. In PD, FMT has shown promising results in improving motor symptoms and gastrointestinal function[23]. The approach addresses multiple pathophysiological mechanisms simultaneously, making it attractive for complex neurodegenerative diseases. Safety considerations are particularly important in elderly patients with neurodegeneration, who may have compromised immune function[24].
Single-strain probiotics including Lactobacillus and Bifidobacterium species have demonstrated cognitive benefits in AD and PD clinical trials[25]. Multi-strain combinations show enhanced effects through synergistic mechanisms, with psychobiotics—probiotics that produce neurotransmitters or their precursors—receiving particular attention[26]. Strain-specific applications are crucial, as not all probiotic strains exert equivalent effects on the gut-brain axis[27].
Dietary fibers including inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) selectively promote beneficial bacteria growth[28]. Resistant starch types 2 and 4 enhance butyrate production and improve gut barrier function[29]. Polyphenol-rich foods enhance beneficial bacteria populations while reducing pro-inflammatory species, providing dual benefits for neurodegeneration prevention[30].
SCFA supplementation with butyrate, propionate, or acetate directly provides the beneficial metabolites that dysbiosis reduces[31]. Bacterial lysates contain immunomodulatory components that can train immune tolerance without viable bacteria[32]. Postbiotic preparations offer advantages in immunocompromised patients where live bacteria pose infection risks[33].
Germ-free mice colonized with AD patient fecal microbiota show increased amyloid-beta plaque deposition and cognitive impairment compared to those colonized with healthy control microbiota[34]. Conversely, probiotic supplementation in APP/PS1 mice reduces amyloid burden, improves synaptic plasticity, and enhances cognitive performance[35]. SCFA administration in 3xTg-AD mice decreases tau hyperphosphorylation through histone deacetylase inhibition[36].
GF mice colonized with PD patient microbiota develop worsened motor deficits and increased alpha-synuclein pathology compared to controls[37]. Probiotic treatment in MPTP-induced PD mice protects dopaminergic neurons and improves motor function[38]. FMT in alpha-synuclein transgenic mice reduces pathological aggregation and neuroinflammation[39].
Germ-free SOD1 mice show delayed disease onset and extended survival compared to conventional mice[40]. Antibiotic-induced microbiome depletion in ALS mice reduces microglial activation and slows disease progression[41]. Butyrate supplementation extends survival and improves motor function in ALS mouse models[42].
| Trial | Phase | Status | Population | Outcome |
|---|---|---|---|---|
| NCT03028103 | Early PD | Completed | 24 patients | Improved motor scores |
| NCT03819227 | AD | Recruiting | 30 patients | Primary: Cognitive function |
| NCT04150588 | PD | Completed | 11 patients | Improved gut motility |
| NCT05432488 | PD | Recruiting | 60 patients | Primary: UPDRS score |
Multiple randomized controlled trials have evaluated probiotic interventions in AD and PD[43]. A 2022 meta-analysis found significant cognitive improvement in AD patients treated with probiotics, particularly multi-strain formulations[44]. Probiotic trials in PD have shown modest improvements in non-motor symptoms including constipation and sleep quality[45].
Individual variability in baseline microbiome composition affects treatment response, requiring personalized approaches[46]. Strain specificity is critical—not all probiotic strains are equivalent, and strain selection must be evidence-based[47]. Delivery challenges include ensuring adequate bacteria survive gastric transit and reach the intestines[48].
FMT is generally safe but carries risks including infection transmission, GI complications, and procedural adverse events[49]. Probiotics pose minimal risk in immunocompetent individuals but can cause bacteremia or fungemia in severely immunocompromised patients[50]. Postbiotics offer similar benefits without infection risk, making them preferable for high-risk populations[51].
FMT contraindications include active infection, severe immunodeficiency, and recent antibiotic exposure[52]. Probiotic contraindications include critical illness, immunosuppression, and central venous catheters[53]. Patients with compromised gut barrier function may experience worsened inflammation from certain probiotic preparations[54].
Regular microbiome testing can track treatment response and guide intervention adjustments[55]. Clinical monitoring should include gastrointestinal symptoms, cognitive/motor function, and inflammatory markers[56].
Microbiome-based therapies show synergy with other interventions[57]. Mediterranean diet enhances beneficial bacteria while providing anti-inflammatory effects[58]. Exercise modifies microbiome composition toward a healthier profile and improves outcomes in neurodegenerative diseases[59]. Prebiotic-probiotic combinations (synbiotics) may provide enhanced benefits over either approach alone[60].
Phase 1 (Weeks 1-4): Dietary modification with prebiotic-rich foods, elimination of processed foods
Phase 2 (Weeks 5-8): Introduction of targeted probiotic or postbiotic supplement
Phase 3 (Weeks 9-12): FMT consideration if initial approaches insufficient
Maintenance: Continued prebiotic supplementation and periodic probiotic cycling
Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019. ↩︎
Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S. A comprehensive review on the role of gut microbiota in Alzheimer's disease. CNS Drugs. 2022. ↩︎
Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci. 2018. ↩︎
Furness JB, Callaghan BP, Rivera LR, Cho HJ. The enteric nervous system and gastrointestinal innervation: local interfaces. Adv Exp Med Biol. 2014. ↩︎
Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018. ↩︎
Sudo N. Stress and gut microbiota: Does prenatal stress program the microbiome? J Reprod Immunol. J Reprod Immunol. 2017. ↩︎
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020. ↩︎
McMillin M, DeMorrow S. Effects of bile acids on neuronal function. Chem Biol Interact. 2016. ↩︎
Vighi G, Marcucci F, Sensi L, Di Cara G, Frati F. Allergy and the gastrointestinal system. Clin Exp Immunol. 2008. ↩︎
Cevenini E, Caruso C, Candore G, et al. Age-related inflammation: The contribution of adipose tissue and lymphoid organs. Immun Ageing. 2010. ↩︎
Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017. ↩︎
Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017. ↩︎
Haran JP, Bhattarai SK, Foley SE, et al. Alzheimer's disease microbiome is associated with dysregulation of the intestinal adaptive immunity. J Transl Med. 2019. ↩︎
Zhan X, Stamova B, Jin LW, et al. Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology. 2016. ↩︎
Matt SM, Allen JM, Lawson MA, Butler LJ, Woods JA. Butyrate and dietary soluble fiber improve age-related executive function and neurodegeneration. Brain Behav Immun. 2018. ↩︎
Stirpe P, Hoffman M, Falup-Pecurariu O, et al. Gut microbiota in Parkinson's disease: Implications for pathogenesis and treatment. J Neurol Sci. 2020. ↩︎
Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003. ↩︎
Keshavarzian A, Engen P, Bonvegna S, Cella M. The gut microbiome in Parkinson's disease: A culprit or a bystander? Prog Neuropsychopharmacol Biol Psychiatry. Prog Neuropsychopharmacol Biol Psychiatry. 2020. ↩︎
Liu B, Fang F, Wang YE, Chen H, Miao L, Ye W. Vagotomy and Parkinson disease: A Swedish register-based study. Neurology. 2017. ↩︎
Fang X, Wang X, Yang S, et al. Evaluation of the microbial diversity in amyotrophic lateral sclerosis. Front Neurol. 2019. ↩︎
Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut microbiome and its metabolites in ALS. Nat Commun. 2019. ↩︎
Zhai CD, Zheng Z, Liu J, et al. Alterations of gut microbiota in amyotrophic lateral sclerosis: A systematic review of human case-control studies. J Transl Med. 2021. ↩︎
Xue LJ, Yang XZ, Tong Q, et al. Fecal microbiota transplantation and its therapeutic potential on Parkinson's disease: A systematic review. Front Neurol. 2022. ↩︎
Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized trial. Hepatology. 2017. ↩︎
Torti JF, Robles-Rivera K, Moncada-Jiménez J, Barrantes-Victoria R, Matarrita-Mata M. Effects of probiotics on cognitive function and emotional states in patients with Alzheimer's disease: A systematic review. J Alzheimers Dis. 2022. ↩︎
Sarkar A, Lehto SM, Harty S, Dinan TG, Burnet PWJ, Cryan JF. Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci. 2016. ↩︎
Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Cell. 2019. ↩︎
Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017. ↩︎
Birt DF, Boylston T, Hendrich S, et al. Resistant starch: Promise for improving human health. Adv Nutr. 2013. ↩︎
Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications for human health. J Nutr Biochem. 2013. ↩︎
Liu J, Wang H, Wang Z, et al. Butyrate improves cognitive function and neuroinflammation in Alzheimer's disease mice by regulating gut microbiota. J Alzheimers Dis. 2022. ↩︎
Zolkiewski J. Bacillus-derived proteases in immune regulation. Immunol Res. 2020. ↩︎
Shenderov BA. Metabiotics: Novel idea or natural development of probiotic concept. Microb Ecol Health Dis. 2013. ↩︎
Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016. ↩︎
Ataie-Kachoie P, Rassa J, Hosseinzadeh S, Nouri M. Therapeutic potential of Lactobacillus species in Alzheimer's disease: A systematic review. J Alzheimer's Dis. 2023. ↩︎
Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function and synaptic plasticity in aging and Alzheimer's disease mouse models. J Alzheimers Dis. 2011. ↩︎
Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016. ↩︎
Srivastava A, Karki N, Verma A, et al. Neuroprotective effects of Lactobacillus plantarum MTCC1325 in a rotenone-induced mouse model of Parkinson's disease. Probiotics Antimicrob Proteins. 2022. ↩︎
Sun MF, Zhu YL, Zhou ZL, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018. ↩︎
Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut microbiome and its metabolites in ALS. Nat Commun. 2019. ↩︎
Wu WL, Adame MD, Clish CB, et al. Microbiome, metabolites and host immunity in ALS. Nat Rev Neurol. 2021. ↩︎
Zhang Y, Liu J, Qiu F, et al. Effects of sodium butyrate on behavioral disorders and gut microbiota in SOD1-G93A transgenic mice. J Neurochem. 2021. ↩︎
Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson's disease: Current evidence and future perspectives. J Transl Med. 2022. ↩︎
Den H, Dong X, Chen M, Zou Z. Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer's disease or mild cognitive impairment: A meta-analysis. Biosci Rep. 2020. ↩︎
Tomasello G, Mazzola M, Leone A, et al. Gut, gut-brain axis and probiotics: A dynamic interplay in Parkinson's disease. J Clin Med. 2020. ↩︎
Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018. ↩︎
Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Cell. 2019. ↩︎
Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: Mechanisms of action and clinical applications. J Clin Gastroenterol. 2013. ↩︎
Paramsothy S, Paramsothy R, Rubin DT, et al. Fecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis. J Crohns Colitis. 2017. ↩︎
Yeh VL, Jovanovich AJ, Grimes M, Brown J. Probiotic-associated sepsis: A case report and review of the literature. Clin Infect Dis. 2020. ↩︎
Vinderola G, Sanders ME, Salminen S. Postbiotics: The concept and their use in healthy populations. Front Microbiol. 2022. ↩︎
Bajaj JS, Barghout V, Hanzel M, et al. A standardized patient decision aid for fecal microbiota transplantation in recurrent Clostridioides difficile infection. Clin Infect Dis. 2021. ↩︎
Doron SN, Tremonti C, Platt M, De Wolfe TJ. Safety of probiotics in immunocompromised patients. Clin Infect Dis. 2021. ↩︎
Anderson JR, Carroll I, Azcarate-Peril MA, et al. A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. Sleep Med. 2017. ↩︎
Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016. ↩︎
Giau VV, Wu SY, Jameri A, et al. Gut microbiota and their neuroinflammatory implications in Alzheimer's disease. Nutrients. 2018. ↩︎
Cerdó T, García-Santos JA, Bermúdez MG, Campoy C. The role of probiotics and prebiotics in the prevention of chronic inflammatory diseases. Int J Mol Sci. 2022. ↩︎
Tosti V, Bertozzi B, Fontana L. Health benefits of the Mediterranean diet: Metabolic and molecular mechanisms. J Gerontol A Biol Sci Med Sci. 2018. ↩︎
Monda V, Villano I, Messina A, et al. Exercise modifies the gut microbiota with positive health effects. Oxid Med Cell Longev. 2017. ↩︎
Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020. ↩︎